Management of Early-Stage TNBC Following Pembrolizumab-Based Neoadjuvant Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
Cancer Treat. Rev 2022 Nov 01;110(xx)102459, RC Bonadio, P Tarantino, L Testa, K Punie, S Pernas, C Barrios, G Curigliano, SM Tolaney, R Barroso-SousaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.